The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index; none of the 19 sources its claims cite is checked for support yet.
The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions
Open accessAbstract
The Global Burden of Disease (GBD) Study 2010 estimated the GBD attributable to 15 categories of skin disease from 1990 to 2010 for 187 countries. For each of the following diseases, we performed systematic literature reviews and analyzed resulting data: eczema, psoriasis, acne vulgaris, pruritus, alopecia areata, decubitus ulcer, urticaria, scabies, fungal skin diseases, impetigo, abscess, and other bacterial skin diseases, cellulitis, viral warts, molluscum contagiosum, and non-melanoma skin cancer. We used disability estimates to determine nonfatal burden. Three skin conditions, fungal skin diseases, other skin and subcutaneous diseases, and acne were in the top 10 most prevalent diseases worldwide in 2010, and eight fell into the top 50; these additional five skin problems were pruritus, eczema, impetigo, scabies, and molluscum contagiosum. Collectively, skin conditions ranged from the 2nd to 11th leading cause of years lived with disability at the country level. At the global level, skin conditions were the fourth leading cause of nonfatal disease burden. Using more data than has been used previously, the burden due to these diseases is enormous in both high- and low-income countries. These results argue strongly to include skin disease prevention and treatment in future global health strategies as a matter of urgency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 19 cited sources checked · 0 supported · 0 flagged
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, the high burden of disability related to eczema remains consistent globally.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > DISCUSSION
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Collectively, skin conditions ranged from being the 2nd to 11th leading cause of years lived with disability at the country level for 2010; they range from 3rd to 28th, taking into account premature deaths.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Disability due to skin disease
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“In Oceania, sub-Saharan Africa, southeast Asia, and the tropical Americas, skin infections assume a higher proportion of the disease burden (Leekassa et al., 2005;Steer et al., 2009).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > DISCUSSION
What the sources say
- Not checked yetcites Leekassa et al., 2005
- Not checked yetcites Steer et al., 2009 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Singapore, Brunei, Hungary, and Sudan experienced the most nonfatal skin disease burden per capita in both 1990 and 2010, and Albania, Lithuania, Romania, and Indonesia the least.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Disability due to skin disease
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Singapore, Brunei, Hungary, and Sudan experienced the most nonfatal skin disease burden per capita in both 1990 and 2010, and Albania, Lithuania, Romania, and Indonesia the least.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Disability due to skin disease
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Across specific causes, ages, and regions, burden is higher among females.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Disability due to skin disease
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Collectively, skin conditions were the 4th leading cause of nonfatal burden expressed as years lost due to disability in 2010; taking into account health loss due to premature death expressed as disability-adjusted life years (DALYs), skin remains the 18th leading cause of health burden worldwide (Tables 1 and 2).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > RESULTS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The leading cause of skin condition DALYs is eczema, when looking across countries, ages, sex, and time because of the combined high prevalence across geographies and population and relatively high average disability weight.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Disability due to skin disease
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Three skin conditions were in the top 10 most prevalent diseases globally in 2010-fungal skin diseases (4th global prevalence ¼ 984,290,432), other skin and subcutaneous diseases (5th), and acne vulgaris (8th global prevalence ¼ 645,499,136; Vos et al., 2012).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Key prevalence findings
What the sources say
- Not checked yetcites Vos et al., 2012 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Three skin conditions, fungal skin diseases, other skin and subcutaneous diseases, and acne were in the top 10 most prevalent diseases worldwide in 2010, and eight fell into the top 50; these additional five skin problems were pruritus, eczema, impetigo, scabies, and molluscum contagiosum.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Abstract
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- It may state two separate claims as one. 24
- Probably not a substantial claim. 21
In the paper
“Three skin conditions were in the top 10 most prevalent diseases globally in 2010-fungal skin diseases (4th global prevalence ¼ 984,290,432), other skin and subcutaneous diseases (5th), and acne vulgaris (8th global prevalence ¼ 645,499,136; Vos et al., 2012).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Key prevalence findings
What the sources say
- Not checked yetcites Vos et al., 2012 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There are further five skin diseases in the top 50 most common causes of diseasepruritus (global prevalence ¼ 279,889,120), eczema (global prevalence ¼ 229,761,000), impetigo (global prevalence ¼ 140,495,000), molluscum contagiosum/warts (global prevalence ¼ 122,601,000), and scabies (global prevalence ¼ 100,625,000).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Key prevalence findings
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“There is also a high burden of skin disease in the elderly above the age of 70 years, where eczema, ulceration, other skin conditions, NMSC, infections, and pruritus are key problems.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > DISCUSSION
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Rates differ substantially by cause across regions: western Europe has the highest prevalence rate for pruritus but the lowest for scabies and eastern sub-Saharan Africa has the highest rates of cellulitis, fungal skin disease, and viral warts but the lowest rates of urticaria.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Disability due to skin disease
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“By age 1 year, skin problems already assume importance as a reason for disability with high levels seen in teenage years.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > DISCUSSION
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There are further five skin diseases in the top 50 most common causes of diseasepruritus (global prevalence ¼ 279,889,120), eczema (global prevalence ¼ 229,761,000), impetigo (global prevalence ¼ 140,495,000), molluscum contagiosum/warts (global prevalence ¼ 122,601,000), and scabies (global prevalence ¼ 100,625,000).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Key prevalence findings
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There are further five skin diseases in the top 50 most common causes of diseasepruritus (global prevalence ¼ 279,889,120), eczema (global prevalence ¼ 229,761,000), impetigo (global prevalence ¼ 140,495,000), molluscum contagiosum/warts (global prevalence ¼ 122,601,000), and scabies (global prevalence ¼ 100,625,000).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Key prevalence findings
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Three skin conditions were in the top 10 most prevalent diseases globally in 2010-fungal skin diseases (4th global prevalence ¼ 984,290,432), other skin and subcutaneous diseases (5th), and acne vulgaris (8th global prevalence ¼ 645,499,136; Vos et al., 2012).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Key prevalence findings
What the sources say
- Not checked yetcites Vos et al., 2012 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There are further five skin diseases in the top 50 most common causes of diseasepruritus (global prevalence ¼ 279,889,120), eczema (global prevalence ¼ 229,761,000), impetigo (global prevalence ¼ 140,495,000), molluscum contagiosum/warts (global prevalence ¼ 122,601,000), and scabies (global prevalence ¼ 100,625,000).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Key prevalence findings
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There are further five skin diseases in the top 50 most common causes of diseasepruritus (global prevalence ¼ 279,889,120), eczema (global prevalence ¼ 229,761,000), impetigo (global prevalence ¼ 140,495,000), molluscum contagiosum/warts (global prevalence ¼ 122,601,000), and scabies (global prevalence ¼ 100,625,000).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Key prevalence findings
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“To ensure uniformity of investigational approach, training was provided by the Institute of Health Metrics, and participants used a common procedure manual.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > MATERIALS AND METHODS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The inclusion criteria were studies that were published between 1980 and 2010 that provided data on relevant disease incidence or prevalence.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Search strategy for identification of studies
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“It pervades all cultures, occurs at all ages, and affects between 30% and 70% of individuals, with even higher rates in at-risk subpopulations (NHANES, 1978;Bickers et al., 2006;Scholfield et al., 2009;Hay and Fuller, 2012).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > INTRODUCTION
What the sources say
- Not checked yetcites NHANES, 1978
- Not checked yetcites Bickers et al., 2006 source
- Not checked yetcites Scholfield et al., 2009
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Data were analyzed using a Baysian meta-regression tool, described below, to harmonize discordant data where multiple estimates were available as well as fill in gaps in geography, time, or age-sex groups, where data were lacking.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > MATERIALS AND METHODS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Disability was derived from an analysis of the comparative impact of the direct disabling consequences of skin disease such as itch and disfigurement against other conditions through a disability weights survey, which involved the use of international panels of volunteers, a telephone-based survey, and a web-based tool.Consistency was demonstrated among all six sources (Salomon et al., 2012).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Disability
What the sources say
- Not checked yetcites Salomon et al., 2012 source
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In terms of age ranges, design of surveys, and even case definitions, data sources did not follow a uniform approach.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > DISCUSSION
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Both measures are applied to whole populations without differentiating for potential variables such as social class or environment.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Disability
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Social factors such as poverty, affluence, inequality, education, and access to health care all have an important role in the epidemiology of skin disease (NHANES, 1978;Williams et al., 1994;Gibbs, 1996;Figueroa et al., 1998;Scholfield et al., 2009).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Analysis of data
What the sources say
- Not checked yetcites NHANES, 1978
- Not checked yetcites Williams et al., 1994
- Not checked yetcites Gibbs, 1996 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Skin diseases of similar severities and extents will affect different subject's lives in strikingly different ways, but for consistency and because of data limitations, the disability weights were defined as such.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Disability
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study group also found, as anticipated, that there were substantial areas of missing and variable quality data at the regional level.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The GBD 2010 Skin Conditions Expert Group provided the lead in data collection and disease consultation for all analyses.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > MATERIALS AND METHODS
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Studies were excluded for the following reasons: Data in study were self-reported unless it had been validated by the diagnosis of a trained physician”
- Also stated in: § Search strategy for identification of studies · plain
“Sample size smaller than 100 Experimental arm of a clinical trial Papers that provided estimates rather than data”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Search strategy for identification of studies
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Also stated in: § Search strategy for identification of studies · plain
In the paper
“Children and their families often bear the brunt of this disease burden (Mahe, 2005).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > INTRODUCTION
What the sources say
- Not checked yetcites Mahe, 2005
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The reviews were carried out in three stages: Round (1): Title/abstract review of hits from searches of medical literature databases.”
- Also stated in: § Search strategy for identification of studies · plain
“Round (2): Whole article review of hits remaining after Round 1. Round (3): Evaluation of articles remaining after Round 2 using agreed quality criteria.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Search strategy for identification of studies
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § Search strategy for identification of studies · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Data were collected in a two stage literature review.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Search strategy for identification of studies
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Ultimately, 895 country-years of data were used, covering 82 countries.Individual cause models used from 16 to 155 country-years worth of data.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Search strategy for identification of studies
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Previously reported GBD estimated annual deaths for skin disease included 66.5 Â 10 3 from bacterial skin infections such as cellulitis and 30.6 Â 10 3 from NMSC (Lozano et al., 2012).”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Key prevalence findings
What the sources say
- Not checked yetcites Lozano et al., 2012 source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Standardized disease definitions were established in several ways.For instance, with atopic dermatitis, within the broader heading of eczema, definitions such as the UK working party definition of AD were used (Williams et al., 1994).Likewise in NMSC histopathological confirmation was required.Elsewhere, the diagnosis of a trained health worker was the standard case definition.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > MATERIALS AND METHODS
What the sources say
- Not checked yetcites Williams et al., 1994
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The classification of skin disease was derived from International Classification of Disease 10, which led to the inclusion of most diseases seen in dermatology clinics under skin, but other skin problems under other medical specialities.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > DISCUSSION
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, this can now be contextualized with all other disease to show that skin conditions are both widespread and among the most prevalent and disabling diseases, and a source of considerable loss of healthy life.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The lower burden due to skin infection in the high-income Asian region highlights the impact of poverty in addition to climate in defining risk.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > DISCUSSION
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For each of the following diseases, we performed systematic literature reviews and analyzed resulting data: eczema, psoriasis, acne vulgaris, pruritus, alopecia areata, decubitus ulcer, urticaria, scabies, fungal skin diseases, impetigo, abscess, and other bacterial skin diseases, cellulitis, viral warts, molluscum contagiosum, and non-melanoma skin cancer.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, the impact of skin diseases must be viewed in terms of local health needs, as regional variations in disability may reflect differences in both prevalence and availability of health care.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > DISCUSSION
Tests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The team reviewed world literature and databases for incidence, prevalence, and remission rates, using acceptable case definitions and stringent criteria for validity of data collection.”
§ The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions > MATERIALS AND METHODS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
The paper relies on this without support.
Skin disease receives comparatively little attention in national and global health policy discussions.
“Yet despite this profound impact, skin disease continues to receive relatively little attention in the national or global health debate.”
The paper relies on this without support.
A few skin conditions account for most of the skin disease burden.
“a pattern dominated by a few conditions accounting for most of the skin disease burden.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the challenges in this field are the vast range of skin pathologies, with more than 2000 recognized skin diseases spanning from inflammatory dermatoses, infections, deposit disease, and neoplastic lesions [1].”
From Artificial Intelligence in Dermatopathology: An Update and Review of the Current Literature (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These models have been proven to provide high sensitivity in the identification of malignant tumors and differentiation of various skin diseases thus being useful for dermatologists (6, 39, 40).”
From Revolutionizing dermatopathology using AI in skin diagnostics: scoping review (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredIn the citing paper
“skin and subcutaneous disorders were the 4th leading cause of nonfatal disease burden worldwide in 2010 and 2013”
From Global Burden of Skin Disease: Inequities and Innovations (2017) · cites this paper as [4]
In the citing paper
“the GBD is based on the ICD classification system, which leads to categorization of certain skin conditions under other entities, for example, melanoma is classified under “cancer.””
From Global Burden of Skin Disease: Inequities and Innovations (2017) · cites this paper as [4]
In the citing paper
“The effects of skin conditions on QoL in resource-replete settings is profound and well-documented”
From Global Burden of Skin Disease: Inequities and Innovations (2017) · cites this paper as [4]
In the citing paper
“the dermatological manifestations of systemic illnesses are not necessarily individually categorized; the burden of lupus erythematosus is therefore entirely included under that of musculoskeletal disease”
From Global Burden of Skin Disease: Inequities and Innovations (2017) · cites this paper as [4]
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Self-citationVos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Self-citation(1996) · Cited by 6,884
Self-citationSalomon, J. A., Vos, T., Hogan, D. R., Gagnon, M., Naghavi, M., Mokdad, A., Begum, N., Shah, R., Karyana, M., Kosen, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61680-8 · Cited by 1,322
Self-citationWILLIAMS, H. C., JBURNEY, P. G., HAY, R. J., ARCHER, C. B., SHIPLEY, M. J., AHUNTER, J. J., BINGHAM, E. A., FINLAY, A. Y., PEMBROKE, A. C., CGRAHAM-BROWN, R. A., et al. (1994) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1994.tb08530.x · Cited by 1,271
Self-citationMeta-analysis of risk factors for cutaneous melanoma: II. Sun exposure
Gandini, S., Sera, F., Cattaruzza, M. S., Pasquini, P., Picconi, O., Boyle, P., & Melchi, C. F. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.10.016 · Cited by 1,266
Bickers (2006) · doi:10.1016/j.jaad.2006.05.048 · Cited by 741
Self-citationUK health performance: findings of the Global Burden of Disease Study 2010
Murray, C. J., Richards, M. A., Newton, J. N., Fenton, K. A., Anderson, H. R., Atkinson, C., Bennett, D., Bernabé, E., Blencowe, H., Bourne, R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60355-4 · Cited by 553
Self-citationIs eczema really on the increase worldwide?
Williams, H. C., Stewart, A. W., von Mutius, E., Cookson, W., & Anderson, H. R. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.11.004 · Cited by 530
Self-citationThe Medical Expenditure Panel Survey
Cohen, J. W., Cohen, S. B., & Banthin, J. S. (2009) · Medical Care · doi:10.1097/mlr.0b013e3181a23e3a · Cited by 343
Flagged first, then by citations
3 of the 31 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- Global Burden of Disease: 2004 Update, 2008, Global Burden of Disease
- Mahe, 2005, Epidemiology and Management of Common Skin Diseases in Children in Developing Countries. WHO
- NHANES, 1978, Skin conditions and related need for medical care among persons 1–74 years . NHANES:, United States, 1971–1974 DHEW Publication 1978 No. (PHS),, pp 79
- Royal College of General Practitioners Research Unit (UK), 2010, Royal College of General Practitioners Research Unit (UK)
- Scholfield, 2009, Skin Conditions in the UK: A Health Needs Assessment
Cited by
Sorted by citations
Items 301–400 of 1,005
Wekalao, J., Mehaney, A., Alarifi, N. S., et al. (2025) · Physica E Low-dimensional Systems and Nanostructures · doi:10.1016/j.physe.2025.116214 · Cited by 38
Assessing skin disease and associated health-related quality of life in a rural Lao community
Wootton, C. I., Bell, S., Philavanh, A., Phommachack, K., Soukavong, M., Kidoikhammouan, S., Walker, S. L., & Mayxay, M. (2018) · BMC Dermatology · doi:10.1186/s12895-018-0079-8 · Cited by 37
Combined Cutaneous Therapy Using Biocompatible Metal-Organic Frameworks
Taherzade, S. D., Rojas, S., Soleimannejad, J., et al. (2020) · Nanomaterials · doi:10.3390/nano10122296 · Cited by 38
Schoenmakers, A., Hambridge, T., van Wijk, R., Kasang, C., Richardus, J. H., Bobosha, K., Mitano, F., Mshana, S. E., Mamo, E., Marega, A., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046125 · Cited by 34
Lasek, A., Bellon, N., Mallet, S., Puzenat, E., Bursztejn, A. ‐., Abasq‐Thomas, C., Mazereeuw‐Hautier, J., Chiavérini, C., Hubiche, T., Raison‐Peyron, N., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18450 · Cited by 38
Pathak, A. K. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/17209.7270 · Cited by 37
Emerging Therapies for Acne Vulgaris
Trivedi, M. K., Bosanac, S. S., Sivamani, R. K., & Larsen, L. N. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0345-x · Cited by 37
He, Z., Marrone, G., Ou, A., et al. (2020) · Health and Quality of Life Outcomes · doi:10.1186/s12955-020-01542-6 · Cited by 37
Liu, X., Cao, Y., & Wang, W. (2023) · JMIR Public Health and Surveillance · doi:10.2196/50114 · Cited by 36
Krueger, J. G., Kircik, L., Hougeir, F. G., Friedman, A., You, X., Lucas, N., Greenberg, S. J., Sweetser, M. T., Castro-Borrero, W., McCroskery, P. A., et al. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0353-2 · Cited by 36
Exosomes as a novel pathway for regulating development and diseases of the skin (Review)
Liu, Y., Wang, H., & Wang, J. (2018) · Biomedical Reports · doi:10.3892/br.2018.1054 · Cited by 39
Ip, A., Müller, I., Geraghty, A. W. A., Platt, D., Little, P. S., & Santer, M. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-041794 · Cited by 36
Hatje, L. K., Richter, C., Blume‐Peytavi, U., et al. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13298 · Cited by 36
Balato, A., Zink, A., Babino, G., Buononato, D., Kiani, C. J., Eyerich, K., Ziehfreund, S., & Scala, E. (2022) · Life · doi:10.3390/life12122026 · Cited by 34
Acne Vulgaris—Novel Treatment Options and Factors Affecting Therapy Adherence: A Narrative Review
Tobiasz, A., Nowicka, D., & Szepietowski, J. C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247535 · Cited by 36
Atopic Dermatitis: A Review of Diagnosis and Treatment
Jeskey, J., Kurien, C., Blunk, H., Sehmi, K., Areti, S., Nguyen, D., & Hostoffer, R. (2024) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-29.6.587 · Cited by 37
Shih, B. B.-J., Nirmal, A. J., Headon, D. J., Akbar, A. N., Mabbott, N. A., & Freeman, T. C. (2016) · The Journal of Pathology · doi:10.1002/path.4864 · Cited by 33
Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation
Kuklinski, L. F., Li, S., Karagas, M. R., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.06.032 · Cited by 35
Călina, I., Demeter, M., Scărișoreanu, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239236 · Cited by 35
Smirnova, J., Montgomery, S., Lindberg, M., Svensson, Å., & von Kobyletzki, L. (2020) · BMC Dermatology · doi:10.1186/s12895-020-00117-8 · Cited by 35
Dai, Y., Tai, Y., Chang, Y.-T., Chen, T., & Chen, M. (2021) · Dermatology · doi:10.1159/000514581 · Cited by 34
Skin-Expressing lncRNAs in Inflammatory Responses
Shefler, A., Patrick, M. T., Wasikowski, R., Chen, J., Sarkar, M. K., Gudjonsson, J. E., & Tsoi, L. C. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.835740 · Cited by 35
Moura, I. B., Grada, A. A., Spittal, W. D., Clark, E., Ewin, D. J., Altringham, J., Fumero, E., Wilcox, M. H., & Buckley, A. M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.901911 · Cited by 36
Priya, S., Tomar, Y., Desai, V. M., & Singhvi, G. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2190095 · Cited by 34
Mansoor, K., Aburjai, T. A., Al-Mamoori, F. F., & Schmidt, M. (2023) · Phytotherapy Research · doi:10.1002/ptr.8019 · Cited by 41
Karimkhani, C., Boyers, L. N., Margolis, D. J., Naghavi, M., Hay, R. J., Williams, H. C., Naldi, L., Coffeng, L. E., Weinstock, M. A., Dunnick, C. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102122 · Cited by 32
Self-citationKiguchi, N., Sukhtankar, D. D., Ding, H., Tanaka, K., Kishioka, S., Peters, C. M., & Ko, M. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229997 · Cited by 34
Isolation of Infiltrating Leukocytes from Mouse Skin Using Enzymatic Digest and Gradient Separation
Benck, C. J., Martinov, T., Fife, B. T., & Chatterjea, D. (2016) · Journal of Visualized Experiments · doi:10.3791/53638 · Cited by 34
Steinke, S., Bruland, P., Blome, C., Osada, N., Dugas, M., Fritz, F., Augustin, M., & Ständer, S. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14910 · Cited by 33
Sotiriou, E., Apalla, Z., Vrani, F., Lazaridou, E., Vakirlis, E., Lallas, A., & Ioannides, D. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14177 · Cited by 34
Pereira, M. P., Lüling, H., Dieckhöfer, A., Steinke, S., Zeidler, C., & Ständer, S. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2789 · Cited by 34
Augustin, M., Goepel, L., Jacobi, A., Bosse, B., Mueller, S., & Hopp, M. (2017) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s141887 · Cited by 34
The Skin—A Common Pathway for Integrating Diagnosis and Management of NTDs
Chandler, D. J., & Fuller, L. C. (2018) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed3030101 · Cited by 32
Emmert, H., Fonfara, M., Rodríguez, E., & Weidinger, S. (2020) · Experimental Dermatology · doi:10.1111/exd.14148 · Cited by 33
Atopic dermatitis, educational attainment and psychological functioning: a national cohort study
Smirnova, J., Kobyletzki, L. B., Lindberg, M., Svensson, Å., Langan, S., & Montgomery, S. (2018) · British Journal of Dermatology · doi:10.1111/bjd.17330 · Cited by 34
Dermatology today and tomorrow: from symptom control to targeted therapy
Blume‐Peytavi, U., Bagot, M., Tennstedt, D., Aroman, M. S., Stockfleth, E., Zlotogorski, A., Mengeaud, V., Schmitt, A.-M., Paul, C. F., Lim, H. W., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15335 · Cited by 36
Topical anti-inflammatory treatments for eczema: network meta-analysis
Lax, S. J., Vogt, E. V., Candy, B., Steele, L., Reynolds, C. M., Stuart, B. L., Parker, R., Axon, E., Roberts, A., Doyle, M., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015064.pub2 · Cited by 38
Self-citationPanagoulias, D. P., Tsoureli‐Nikita, E., Virvou, M. K., & Tsihrintzis, G. A. (2025) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2025.105898 · Cited by 41
Onychomycosis in Israel: epidemiological aspects
Segal, R., Shemer, A., Hochberg, M., et al. (2015) · Mycoses · doi:10.1111/myc.12287 · Cited by 33
Mohammadzadeh, I., Riahi, S. M., Saber, V., et al. (2018) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/try094 · Cited by 33
Gemeda, N., Tadele, A., Lemma, H., Girma, B., Addis, G., Tesfaye, B., Abebe, A., Gemechu, W., Yirsaw, K., Teka, F., et al. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/9812093 · Cited by 38
Fractional Laser-Mediated siRNA Delivery for Mitigating Psoriasis-like Lesions via IL-6 Silencing
Lee, W.-R., Lin, Y.-K., Alalaiwe, A. S., Wang, P.-W., Liu, P.-Y., & Fang, J. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.11.013 · Cited by 34
Schonmann, Y., Mansfield, K. E., Mulick, A. R., Roberts, A., Smeeth, L. L., Langan, S., & Nitsch, D. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20067 · Cited by 34
Amare, H. H., & Lindtjørn, B. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009816 · Cited by 35
Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
Lytvyn, Y., & Gooderham, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020568 · Cited by 39
Clinical aspects and management of chronic itch
Zeidler, C., Raap, U., Witte, F., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.04.018 · Cited by 32
Fundamentals of Skin Bioimpedances
Presti, A. L., Montoya, N. A., Criscuolo, V., Khan, G., Khan, U., Vecchione, R., & Falconi, C. (2023) · Advanced Materials · doi:10.1002/adma.202302127 · Cited by 34
Global mortality from conditions with skin manifestations
Boyers, L. N., Karimkhani, C., Naghavi, M., Sherwood, D., Margolis, D. J., Hay, R. J., Williams, H. C., Naldi, L., Coffeng, L. E., Weinstock, M. A., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.08.022 · Cited by 31
Self-citationMuñoz, F. C., Cervantes, M. M., Cervantes‐García, D., Jiménez, M., Ventura‐Juárez, J., & Salinas, E. (2017) · Journal of Immunology Research · doi:10.1155/2017/6935402 · Cited by 32
Spuls, P. I., Gerbens, L. A. A., Apfelbacher, C., Wall, D. R., Arents, B. W. M., Barbarot, S., Roberts, A., Deleuran, M. S., Middelkamp-Hup, M. A., Vestergaard, C., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.014 · Cited by 32
Health‐related quality of life in patients with cutaneous T‐cell lymphoma?
Holahan, H. M., Farah, R. S., Fitz, S. R., et al. (2018) · International Journal of Dermatology · doi:10.1111/ijd.14132 · Cited by 32
Otašević, S., Momčilović, S., Golubović, M., et al. (2019) · Mycoses · doi:10.1111/myc.12900 · Cited by 32
Self-citationBumah, V. V., Masson‐Meyers, D. S., Tong, W. G., et al. (2019) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2019.111701 · Cited by 32
Schielein, M. C., Christl, J., Sitaru, S., Pilz, A. C., Kaczmarczyk, R., Biedermann, T., Lasser, T., & Zink, A. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18853 · Cited by 31
A review of four common medicinal plants used to treat eczema
Shadi, T. Z., & Zari, T. A. (2015) · Journal of Medicinal Plants Research · doi:10.5897/jmpr2015.5831 · Cited by 32
Homayoon, D., Hiebler‐Ragger, M., Zenker, M., Weger, W., Unterrainer, ., & Aberer, E. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3563 · Cited by 44
Bajwa, H., Baghchechi, M., Mujahid, M. S., Dufour, M. K., Langan, S., & Abuabara, K. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.09.018 · Cited by 32
Misery, L., Schut, C., Balieva, F., Bobko, S., Reich, A., Sampogna, F., Altunay, İ. K., Dalgard, F. J., Gieler, U., Kupfer, J. P., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19427 · Cited by 32
Punica granatum L. (Pomegranate) Extracts and Their Effects on Healthy and Diseased Skin
Dimitrijevic, J., Tomovic, M. T., Bradić, J., Petrović, A., Jakovljevic, V. L., Andjic, M. M., Živković, J., Milošević, S. Đ., Igor, S., & Dragicevic-Curic, N. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040458 · Cited by 46
Meschini, S., Pellegrini, E., Maestri, C. A., Condello, M., Bettotti, P., Condello, G., & Scarpa, M. (2019) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.34423 · Cited by 31
Preparation, Characterisation, and Topical Delivery of Terbinafine
Monjur-Al-Hossain, A. S. M., Sil, B. C., Iliopoulos, F., et al. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11100548 · Cited by 31
Bacillomycin D effectively controls growth of Malassezia globosa by disrupting the cell membrane
Wu, T., Chen, M., Zhou, L., Lü, F., Bie, X., & Lu, Z. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10462-w · Cited by 30
Epidemiologic Burden of Skin Cancer in the US and Worldwide
Rundle, C. W., Militello, M., Barber, C. M., Presley, C. L., Rietcheck, H. R., & Dellavalle, R. P. (2020) · Current Dermatology Reports · doi:10.1007/s13671-020-00311-4 · Cited by 31
Self-citationSobczyk, M., Richardson, T. G., Zuber, V., Min, J. L., GoDMC, Gaunt, T. R., & Paternoster, L. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.03.027 · Cited by 28
Lin, L., Chen, Y., Wei, J., Wu, S., Wu, S., Jin, J., Dong, G., & Cai, L. (2022) · Environmental Research · doi:10.1016/j.envres.2022.114003 · Cited by 29
Jiang, Z. M., Jin, S., Fan, X., Cao, K., Liu, Y., Wang, X., Ma, Y., & Xiang, L. F. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s374692 · Cited by 29
van de Meeberg, M. M., Hebing, R. C. F., Nurmohamed, M. T., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15579 · Cited by 31
Development and validation of a new tool to assess the Burden of Sensitive Skin (Bo SS )
Misery, L., Jourdan, E., Abadie, S., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15186 · Cited by 31
Hay, R. M. A., Shalaby, K., Zaher, H. A. E.-M., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011946 · Cited by 31
Self-citationTranscriptome-microRNA analysis of Sarcoptes scabiei and host immune response
He, R., Gu, X., Lai, W., Peng, X., & Yang, G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177733 · Cited by 29
Bozorg, B. D., Bhattaccharjee, S. A., Somayaji, M. R., & Banga, A. K. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00897-7 · Cited by 31
New insights into immunity to skin fungi shape our understanding of health and disease
Ruchti, F., & LeibundGut‐Landmann, S. (2023) · Parasite Immunology · doi:10.1111/pim.12948 · Cited by 31
Misery, L., Sénéschal, J., Reguiaï, Z., et al. (2018) · Acta Dermato Venereologica · doi:10.2340/00015555-2940 · Cited by 30
Sirtuin6 inhibits c‐triggered inflammation through TLR4 abrogation regulated by ROS and TRPV1/CGRP
Zhang, R., Li, H., Guo, Q., Zhang, L., Zhu, J., & Ji, J. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27176 · Cited by 30
dos Santos, D. S., Barreto, R. D. S. S., Serafini, M. R., Gouveia, D. N., Marques, R. S., Nascimento, L. D. C., Nascimento, J. D. C., & Guimarães, A. G. (2019) · Fitoterapia · doi:10.1016/j.fitote.2019.104267 · Cited by 28
Worsley, P. R., Crielaard, H., Oomens, C. W. J., et al. (2020) · Microcirculation · doi:10.1111/micc.12645 · Cited by 29
Representation of skin color in dermatology-related Google image searches
Kurtti, A., Austin, E., & Jagdeo, J. R. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.03.036 · Cited by 29
IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses
Roh, Y. S., Choi, J., Sutaria, N. H., Belzberg, M., Kwatra, M. M., & Kwatra, S. G. (2021) · Drugs · doi:10.1007/s40265-021-01521-1 · Cited by 30
Skin Disease Analysis With Limited Data in Particular Rosacea: A Review and Recommended Framework
Mohanty, A., Sutherland, A., Bezbradica, M., & Javidnia, H. (2022) · IEEE Access · doi:10.1109/access.2022.3165574 · Cited by 31
Johnson, M. K. (2020) · Advanced Emergency Nursing Journal · doi:10.1097/tme.0000000000000320 · Cited by 29
Printable personalized drug delivery patch for the topical therapy of skin diseases
Shao, J., Zhang, J., Villasis, N. A., Li, X., Chen, G., Chen, G., Yu, J., Zhang, Y., Wang, J., Gao, Y., et al. (2022) · Matter · doi:10.1016/j.matt.2022.09.018 · Cited by 29
Bidirectional relationships between psychological health and dermatological conditions in children
Mitchell, A. E. (2018) · Psychology Research and Behavior Management · doi:10.2147/prbm.s117583 · Cited by 29
An interprofessional approach to pressure ulcer prevention: a knowledge and attitudes evaluation
Clarkson, P., Worsley, P. R., Schoonhoven, L., et al. (2019) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s195366 · Cited by 29
Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development
Copley‐Merriman, C., Zelt, S., Clark, M., & Gnanasakthy, A. (2016) · Patient · doi:10.1007/s40271-016-0196-6 · Cited by 28
Contribution of health care factors to the burden of skin disease in the United States
Lim, H. W., Collins, S. A. B., Resneck, J., Bolognia, J. L., Hodge, J. A., Rohrer, T. E., Beek, M. J. V., Margolis, D. J., Sober, A. J., Weinstock, M. A., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.03.006 · Cited by 28
Self-citationJang, H., Park, S., Kim, M. S., Yon, D. K., Lee, S. W., Koyanagi, A., Kostev, K., Shin, J. I., & Smith, L. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.13958 · Cited by 25
Gu, X., Jing, D., Xiao, Y., Zhou, G., Yang, S., Liu, H., Chen, X., & Shen, M. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.114683 · Cited by 28
Burden of Disease; the Current Status of the Diagnosis and Management of Atopic Dermatitis in China
Gu, C., Yao, X., & Li, W. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165370 · Cited by 29
Ingebrigtsen, S. G., Škalko‐Basnet, N., & Holsæter, A. M. (2015) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2015.1135940 · Cited by 28
A systematic review of isotretinoin dosing in acne vulgaris
Daly, A. U., Gonçalves, R. B., Lau, E., Bowers, J., Hussaini, N., Charalambides, M., Coumbe, J., Flohr, C., & Layton, A. (2023) · JEADV Clinical Practice · doi:10.1002/jvc2.154 · Cited by 28
HI-MViT: A lightweight model for explainable skin disease classification based on modified MobileViT
Ding, Y., Yi, Z., Li, M., Long, J., Lei, S., Guo, Y., Fan, P., Zuo, C., & Wang, Y. (2023) · Digital Health · doi:10.1177/20552076231207197 · Cited by 31
Hu, C., Zeng, D., Huang, Y., Deng, Q., Liu, S., Zhou, W., & Zhou, W. (2023) · Inflammation · doi:10.1007/s10753-023-01955-7 · Cited by 29
Kalarikkal, S. P., Kumar, M. N., Rajendran, S., Bethi, C. M. S., Ravilla, J., Janakiraman, N., & Sundaram, G. M. (2025) · iScience · doi:10.1016/j.isci.2025.112556 · Cited by 31
White, L., Lanza, S., Middleton, J., Hewitt, K., FREIRE-MORAN, L., Edge, C., Nicholls, M., Rajan-Iyer, J., & Cassell, J. (2016) · Epidemiology and Infection · doi:10.1017/s0950268816001746 · Cited by 27
Davies, E. J., Rogers, N. K., Lloyd-Lavery, A., Grindlay, D. J. C., & Thomas, K. S. (2018) · Clinical and Experimental Dermatology · doi:10.1111/ced.13377 · Cited by 26
Fraser, T. A., Carver, S., Martin, A. M., Mounsey, K. E., Polkinghorne, A., & Jelocnik, M. (2018) · PeerJ · doi:10.7717/peerj.5291 · Cited by 28
Novel drugs for the treatment of chronic pruritus
Pereira, M. P., & Ständer, S. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1548606 · Cited by 26
Harvey, I. B., Wang, X., & Fremont, D. H. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007711 · Cited by 30
Gautam, R., Yang, S., Maharjan, A., Jo, J., Acharya, M., Heo, Y., & Kim, C. (2021) · Frontiers in Toxicology · doi:10.3389/ftox.2021.649666 · Cited by 25
Terbinafin-resistente Dermatophytosen und Onychomykose durch Trichophyton rubrum
Appelt, L., Nenoff, P., Uhrlaß, S., et al. (2021) · Der Hautarzt · doi:10.1007/s00105-021-04879-1 · Cited by 27
Metadata
- Authors
- Hay, R. J., Johns, N. E., Williams, H. C., Bolliger, I. W., Dellavalle, R. P., Margolis, D. J., Marks, R., Naldi, L., Weinstock, M. A., Wulf, S. K., Michaud, C., J.L. Murray, C., & Naghavi, M.
- Affiliations
- University of Washington (US)
- University of Nottingham (GB)
- Denver VA Medical Center (US)
- University of Pennsylvania (US)
- Skin and Cancer Foundation (AU)
- Ospedale Papa Giovanni XXIII (IT)
- Brown University (US)
- China Medical Board (US)
- Corresponding author
- Hay, Roderick J.
- ORCID
- Venue
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 134
- Issue
- 6
- Pages
- 1527-1534
- ISSN
- 0022-202X (ISSN-L)
- OpenAlex
- W2051521434
- Semantic Scholar
- 5f720423986eece0d00d0b522e9e594f0a7ca829
- Cited by
- 1,706
- References
- 31
- Citations by year
- 2026: 144 · 2025: 178 · 2024: 185 · 2023: 202 · 2022: 201 · 2021: 144 · 2020: 166 · 2019: 116 · 2018: 113 · 2017: 90 · 2016: 86 · 2015: 57 · 2014: 21
- FWCI
- 64.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Investigative Dermatology (publishedVersion)
- PubMed (publishedVersion)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- Bill and Melinda Gates Foundation
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Infectious Diseases › Dermatological diseases and infestations
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Global Health and Epidemiology
- Keywords
- skin diseases, global burden of disease, prevalence, years lived with disability, atopic dermatitis, psoriasis, acne, pruritus, alopecia areata, pressure ulcers, urticaria, scabies, fungal skin infection, impetigo, bacterial skin infections, cellulitis, viral warts, molluscum contagiosum, non-melanoma skin cancer
- MeSH terms
- Dermatology, Female, Disabled Persons, Persons with Disabilities, Humans, Male, Mortality, Skin, Skin Diseases, Skin Neoplasms, Global Health, Prevalence, Cost of Illness, Quality-Adjusted Life Years
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
